Pyruvate Kinase Deficiency
An inherited enzyme defect in red blood cells that leads to chronic hemolytic anemia, ranging from mild to transfusion-dependent disease.
- Specialist hematology review
- Access to PK-activator therapy
- Transfusion & splenectomy guidance
- Inheritance
- Autosomal Recessive (PKLR gene)
- Most Common In
- Diagnosed in infancy or childhood
- Disease Pattern
- Lifelong chronic hemolysis
- Advanced Therapies
- Mitapivat (PK activator), Gene Therapy in Trials
Condition Overview
Pyruvate kinase (PK) deficiency is an inherited disorder caused by mutations in the PKLR gene, which provides instructions for an enzyme that red blood cells need to produce energy. Without enough functioning enzyme, red blood cells become fragile and are destroyed earlier than normal, a process called hemolysis.
The condition is present from birth, though severity varies widely โ some people are diagnosed as newborns with severe anemia and jaundice, while others are not identified until later in life when mild fatigue or gallstones prompt evaluation. Because PK deficiency is rare and its symptoms overlap with other hemolytic anemias, accurate diagnosis often requires specialized enzyme assays and genetic testing.
Lifelong management focuses on monitoring hemoglobin levels, preventing complications of chronic hemolysis such as iron overload and gallstones, and โ for eligible patients โ using newer enzyme-activating medications that can reduce hemolysis at its source.
Types and Subtypes
Pyruvate kinase deficiency is generally described by the severity and timing of disease onset rather than distinct biological subtypes, since all forms stem from reduced PK enzyme activity.
Symptoms and Signs
Symptoms reflect chronic anemia and the breakdown of red blood cells, and they can appear at any age.
Causes and Risk Factors
Pyruvate kinase deficiency is a purely genetic condition; it is not caused by lifestyle, diet, or environmental exposures.
Diagnosis and Investigations
Diagnosis combines blood tests that point toward hemolysis with specific enzyme and genetic studies that confirm PK deficiency and rule out other causes.
Disease Severity Classification
PK deficiency does not use a cancer-style staging system. Instead, clinicians classify disease by transfusion needs and clinical severity to guide management.
Standard Treatment Options
Treatment is tailored to severity, ranging from monitoring alone to regular transfusion support and surgical options for select patients.
Advanced and Emerging Treatment Options
A newer class of medicines that directly activates the deficient enzyme has changed the treatment landscape for eligible adults with PK deficiency.
Precision Medicine
Mitapivat (PK activator)
An oral medication that allosterically activates pyruvate kinase, improving enzyme function and reducing hemolysis in adults with certain non-deletional PKLR mutations.
Gene Therapy
Investigational gene therapy approaches
Early-phase research is exploring gene addition or correction strategies aimed at providing a lasting source of functional PK enzyme.
Cellular Therapy
Hematopoietic stem cell transplant
Curative in principle by replacing the patient's blood-forming cells, but reserved for select severe cases due to transplant-related risks.
Biomarkers and Precision Medicine
Genetic and biochemical markers help confirm diagnosis, predict severity, and identify candidates for enzyme-activator therapy.
When a Second Opinion May Be Important
Because PK deficiency is rare, a specialist hematology second opinion can help confirm diagnosis and identify the most appropriate, individualized treatment path.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in PK deficiency vary widely depending on genotype, severity at diagnosis, and access to specialized care. Many patients, including those with significant transfusion needs in childhood, go on to lead active lives with appropriate long-term management.
Supportive Care and Living With Pyruvate Kinase Deficiency
Ongoing supportive measures help manage the day-to-day impact of chronic hemolysis and reduce long-term complications.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with pyruvate kinase deficiency access specialist hematology review, second opinions on transfusion or splenectomy decisions, and coordination for enzyme-activator or transplant evaluation.
Get a free case reviewFrequently Asked Questions
It is an inherited enzyme disorder of red blood cells that causes chronic hemolytic anemia due to mutations in the PKLR gene.
No. Both are inherited red blood cell enzyme disorders that cause hemolysis, but they involve different enzymes, different genes, and different triggers, and are diagnosed with separate tests.
Diagnosis typically combines a blood smear and hemolysis markers with a specific PK enzyme activity assay and genetic testing of the PKLR gene.
Not necessarily. Transfusion needs depend on disease severity and genotype โ some children need regular transfusions in infancy that lessen over time, while others have mild disease without regular transfusion.
Mitapivat is an oral PK-activator medication approved for adults with PK deficiency who carry specific PKLR mutation combinations; a hematologist can determine eligibility.
Splenectomy does not cure the underlying enzyme defect but can meaningfully reduce red cell destruction and transfusion needs in some patients.
Hematopoietic stem cell transplant can be curative in select severe cases, while most patients are managed long-term with supportive and enzyme-targeted therapies.
Yes, it follows an autosomal recessive pattern, meaning a child must inherit a mutated PKLR gene copy from each parent to be affected.
Key complications include gallstones, iron overload, aplastic crises triggered by infection, and infection risk after splenectomy.
Yes. CancerFax can help coordinate medical report review, connect you with hematology specialists for a second opinion, and support access to enzyme-activator therapy or transplant evaluation, including cross-border coordination where needed.
Get Expert Guidance for Pyruvate Kinase Deficiency
Share your reports with our team to explore specialist review, treatment options, and second opinion support.